BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease,...
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 806 1445
Address:
5885 Hollis Street, Suite 370, EmeryVille, United States
